HEPATITIS C DIRECT ACTING ANTIVIRALS (DAA)

Prior Authorization required for all Hepatitis C DAA agents:

Preferred Agent(s): Mavyret (for all genotypes) and Vosevi (for patients previously treated with NS5A inhibitors; also indicated for genotype 1a or 3 previously treated with sofosbuvir without an NS5A inhibitor).

If prescribing non-preferred alternatives, please provide documentation of medical reason(s) why the patient is unable to take the preferred medication) otherwise, all requests for a non-preferred agent will be redirected to a preferred agent(s).

LENGTH OF AUTHORIZATION: 8 weeks, 12 weeks or 16 weeks.

INITIAL REVIEW CRITERIA:

1. Adult patient age ≥ 18 years of age or 12 years of age and older for Mavyret (or weighing 45kg or more) AND
2. Prescribed by or in consultation with a hepatologist, gastroenterologist, infectious disease specialist or transplant physician; AND
3. Patient has no history of the requested medication (no claims history or reference in medical records to previous trial and failure of requested medication).
4. Submission of Hepatitis B surface antigen screening to verify no reactivation.
5. One of the following:
   - Patient has abstained from the use of illicit drugs and alcohol for a minimum of one month as evidenced by negative urine or blood confirmation tests collected within the past 30 days, prior to initiation of therapy (results must be submitted with request);
     - If the test result submitted is positive the reviewer must review claims history or medical records to determine if medications are prescribed. If so proceed to next step (#6).
   - OR
   - Patient is receiving substance or alcohol abuse counseling services or seeing an addiction specialist as an adjunct to HCV treatment and it is documented in the medical records; AND
6. Baseline HCV RNA must be submitted with a collection date within the past six months. Prescriber must submit lab documentation indicating HCV genotype and quantitative viral load.
7. Patient meets the diagnosis and criteria outlined in Dosing and Administration below; AND
8. Patient commits to the documented planned course of treatment including anticipated blood tests and visits, during and after treatment; AND
9. No early refills will be allowed due to lost, stolen medications or vacation override.
10. Lab results (HCV RNA) are recommended after 4 weeks of therapy and at 12 weeks following completion of therapy. The medication should not be discontinued or interrupted if HCV RNA levels are not available during treatment or are not performed.
11. Females of childbearing potential must have a negative pregnancy test collected within 30 days prior to the initiation of therapy with ribavirin; AND

12. For HIV-1 co-infected patients, patients must have the following:
   • Documented HIV-1 diagnosis, AND
   • CD4 count greater than 500 cells/mm³, if patient is not taking antiretroviral therapy; OR
   • CD4 count greater than 200 cells/mm³, if patient is virologically suppressed (e.g., HIV RNA < 200 copies/mL).

DECOMPENSATED CIRRHOSIS

1. Must adhere to the initial review criteria above with the exception dosing and administration must reflect the FDA indications for decompensated cirrhosis.
2. Only medication with the FDA approved indication of decompensated cirrhosis and the specified genotype will be approved.
3. Additional supportive information is available at Infectious Disease Society of America and American Association for the Study of Liver Diseases (IDSA/AASLD) guidelines: https://www.hcvguidelines.org/.

RETREATMENT REVIEW CRITERIA AFTER FAILURE WITH A DAA AGENT:

1. Prescribed by or in consultation with a hepatologist, gastroenterologist, infectious disease specialist or transplant physician; AND
2. Member was adherent to previous therapy as evidenced by pharmacy claims; AND
3. Submission of Hepatitis B surface antigen screening/test to verify no reactivation
4. Submission of psychological support/treatment for a minimum of six months for substance abuse related failure (i.e. NA, AA)
5. One of the Following:
   ▪ Evidence of failure to achieve a sustained virologic response (SVR) or lack of efficacy during treatment:
     o Must submit proof showing detectable HCV RNA in the serum, when assessed by a sensitive polymerase chain reaction (PCR) assay, 12 or more weeks after completing treatment; or a 10-fold increase of viral load at week 6 of treatment; OR
   ▪ Evidence of adverse event that required therapy discontinuation:
     o Laboratory results (eg: CBC, LFTs, etc.) and/or clinical presentation, AND
     o After proper management, there was no improvement of adverse effect (eg: ribavirin-induced anemia should be managed by temporarily withholding ribavirin and/or treating with erythropoiesis-stimulating agent, if indicated, and not discontinuing other DAA)
     o A MedWatch Voluntary Report must be submitted (copy of the report must be submitted with request); AND
6. Patient has abstained from the use of illicit drugs and alcohol for a minimum of 3 months as evidenced by negative urine or blood confirmation tests, collected monthly for the past 90 days prior to initiation of therapy (results must be submitted with request);
7. Baseline HCV RNA following initial treatment must be submitted with a collection date within the past three months. Prescriber must submit lab documentation indicating HCV genotype and quantitative viral load. AND
8. Patient commits to the documented planned course of treatment including anticipated blood tests and visits, during and after treatment; AND
9. Females of childbearing potential must have a negative pregnancy test collected within 30 days prior to the initiation of therapy OR medical records must be submitted documenting pregnancy status for ribavirin therapy; **AND**

10. For HIV-1 co-infected patients, patients must have the following:
   - Documented HIV-1 diagnosis, **AND**
   - CD4 count greater than 500 cells/mm³, if patient is not taking antiretroviral therapy; **OR**
   - CD4 count greater than 200 cells/mm³, if patient is virologically suppressed (e.g., HIV RNA < 200 copies/mL)

11. No early refills will be allowed due to lost, stolen medications or vacation override.

**Denial Criteria for retreatment**

1) Short life expectancy (less than 12 months) that cannot be remediated by treating HCV infection, by transplantation, or by other directed therapy
2) Member continues to engage in high risk behavior and/or experienced reinfection secondary to high risk behavior
3) Member was non-adherent to initial regimen as evidenced by medical record and/or pharmacy claims;

**MAVYRET**

<table>
<thead>
<tr>
<th>HCV &amp; HCV/HIV-1 co-infection</th>
<th>Treatment Naive</th>
<th>Regimen and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No cirrhosis</td>
<td>Compensated cirrhosis (Child-Pugh A), or liver or kidney transplant recipients.</td>
<td>12 weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCV &amp; HCV/HIV-1 co-infection</th>
<th>Treatment experienced</th>
<th>Regimen and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1</td>
<td>No cirrhosis</td>
<td>Compensated cirrhosis (Child Pugh-A), or liver or kidney transplant recipients.</td>
</tr>
<tr>
<td>Previous regimens with an NS5A inhibitor (e.g. ledipasvir and sofosbuvir or daclatasvir with pegylated interferon and ribavirin) without prior treatment with a NS3/4A protease inhibitor.</td>
<td>16 weeks</td>
<td>16 weeks</td>
</tr>
<tr>
<td>Genotype 1</td>
<td>No cirrhosis</td>
<td>Compensated cirrhosis (Child-Pugh A)</td>
</tr>
<tr>
<td>Previous regimens with an NS3/4A protease inhibitor (e.g. telaprevir, boceprevir or simeprevir) without prior treatment with an NS5A inhibitor.</td>
<td>12 weeks</td>
<td>12 weeks</td>
</tr>
</tbody>
</table>
**Genotype 1, 2, 4, 5 or 6**

- Previous regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir.
- No cirrhosis
- Compensated cirrhosis (Child-Pugh A), or liver or kidney transplant recipients.
- Dosage: 8 weeks
- 12 weeks

| Genotype 3 |
|-----------------|------------------|-----------------|------------------|
| Previous regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir. | No cirrhosis | Compensated cirrhosis (Child-Pugh A), or liver or kidney transplant recipients. | 16 weeks |
| 16 weeks |

**DOSING AND ADMINISTRATION:** TAKE BY MOUTH THREE TABLETS ONCE DAILY WITH FOOD.

---

**VOSEVI**

<table>
<thead>
<tr>
<th>HCV &amp; HCV/HIV-1 co-infection</th>
<th>Treatment Experienced</th>
<th>Regimen and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1a or 3</td>
<td>No cirrhosis or compensated cirrhosis (Child Pugh-A) previous regimen with sofosbuvir without an NS5A inhibitor.</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Genotype 1-6</td>
<td>No cirrhosis or compensated cirrhosis (Child Pugh-A) previous regimen with an NS5A inhibitor (e.g. daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir).</td>
<td>12 weeks</td>
</tr>
</tbody>
</table>

**DOSING AND ADMINISTRATION:** TAKE BY MOUTH ONE TABLET DAILY WITH FOOD.